Purchase this article with an account.
S. L. Maskin, C. Warsinski; Long Term Safety and Retreatment Data After Intraductal Meibomian Gland Probing for Obstructive Meibomian Gland Dysfunction. Invest. Ophthalmol. Vis. Sci. 2010;51(13):6283.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To take a retrospective look at the longer term follow up of the initial 25 patients treated with intraductal meibomian gland probing (MGP) for obstructive MGD reported at ARVO 2009 meeting.
Charts were reviewed looking at numbers of patients with follow up, length of follow up, status of symptoms at last follow up and number of patients needing retreatment.
Twenty four (96%) of the initial group of 25 patients had at least 6 months follow up. Follow up was by office exam in 18, phone in 3 and email in 3 patients. Seventeen patients did not need retreatment (71%). The range of follow up for non retreated patients was 6 to 26 months with average 18.4 months (SD= 5.90). The 17 patients had a total of 29 lids treated. Seven patients needing retreatment (29%), had an overall range of 6 to 25 months follow up with average 15.4 months (SD =5.91) . These seven patients had nine lids retreated with the average interval for first retreatment 8.55 months (SD= 6.19) with range of 1 to 18 months. Three of these nine lids were retreated a second time. At time of last follow up, all patients reported ongoing improvement. No patient had worse symptoms and no adverse sequelae of probing were noted.
With an average follow up of almost 1 ½ years there have been no long term adverse effects of Meibomian Gland Probing. The majority of patients in this retrospective follow up did not require retreatment by a ratio of 2.44:1.
This PDF is available to Subscribers Only